Company news
Protalix Biotherapeutics, Inc. (de) (AMEX:PLX) news
Protalix Biotherapeutics, Inc. (de) news releases on 6ix. Latest, Aug 12, 2026: Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business…
Press releases & updates
Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results
August 12, 2026
Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026
August 5, 2026
Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results
May 13, 2026
Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026
May 6, 2026
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results
March 18, 2026
Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026
March 11, 2026
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) ▼
March 9, 2026
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU
January 30, 2026
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU
January 30, 2026
Protalix BioTherapeutics Letter to Stockholders
January 5, 2026
PLX: Secarna’s Antisense Oligonucleotide Discovery Collaboration
December 22, 2025
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement
December 17, 2025
Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results
November 13, 2025
Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025
November 6, 2025
Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU
November 3, 2025
Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU
October 17, 2025
Protalix BioTherapeutics to Present at Investor Summit Virtual
September 11, 2025
Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025
Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results
August 14, 2025
Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025
August 7, 2025
Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer
July 21, 2025
Protalix BioTherapeutics Added to Russell 3000® and 2000 Indexes®
June 30, 2025
Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
May 14, 2025
Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results
May 9, 2025
Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025
May 5, 2025